Lower response to the hepatitis B vaccine in future inflammatory bowel disease patients

Ardesia, Marco; Costantino, Giuseppe; Fries, Walter

doi:10.1097/meg.0000000000000670

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important issue is the relationship between IBD and HBsAb status in vaccinated IBD patients; we confirm the finding of Waszczuk et al [ 17 ] who reported a seroprotection rate of 54%, underlining that our patients were vaccinated long before the diagnosis of IBD was made. This confirms our previous finding in a much smaller cohort [ 26 ].…”

Section: Discussionsupporting

confidence: 93%

Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy

Ardesia

Costantino

Mondello

et al. 2017

Gastroenterology Research and Practice

Self Cite

View full text Add to dashboard Cite

Background With the introduction of more potent immunosuppressive agents in inflammatory bowel disease, prevention of opportunistic infections has become necessary by introducing screening programs. Prevalence of the most important infectious agents may vary in different geographical areas. The aim of our study was to assess the immune status for hepatitis B, varicella, mononucleosis, and cytomegalovirus infection together with the determination of the hepatitis C and tuberculosis status in Southern Italy. Methods Prevalence of latent tuberculosis, together with serology of hepatitis B and C, Epstein-Barr virus, varicella zoster, and cytomegalovirus were collected by analysing retrospectively the clinical charts of IBD patients. Data were integrated with demographic and clinical features. Results Data from 509 IBD patients divided in two age groups showed a prevalence of HBV infection in nonvaccinated patients of 9%. Seroprotection (HBsAb) in vaccinated IBD patients was lower (p < 0.0001) compared with that in controls. Prevalences of herpesvirus infections fluctuate between 51% (CMV) and 85% (EBV) and 84% (VZV) in younger patients. Latent tuberculosis and hepatitis C infection were found only in patients > 37 years of age. Conclusions In younger patients, high susceptibility rates for primary herpesvirus infections should determine the choice of treatment. Loss of HBV seroprotection in already vaccinated patients should be considered for booster vaccination programs.

show abstract

Section: Discussionsupporting

confidence: 93%

Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy

Ardesia

Costantino

Mondello

et al. 2017

Gastroenterology Research and Practice

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, it has been demonstrated that response rates after HBV vaccination are reduced compared with healthy individuals[ 53 ]. Indeed, it was shown that patients with future diagnosis of IBD had suboptimal vaccination response even before the clinical manifestation of IBD[ 54 ]. Based on a meta-analysis by Jiang et al [ 53 ], which included 13 studies with 1688 patients, the pooled response rate to vaccination for HBV among IBD patients was 61%.…”

Section: Management Of Hbv Infection In Patients With Ibdmentioning

confidence: 99%

Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment

Axiaris

Zampeli

Michopoulos

et al. 2021

WJG

View full text Add to dashboard Cite

Hepatitis B remains a significant global clinical problem, despite the implementation of safe and effective vaccination programs. The prevalence of hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD) largely follows the regional epidemiologic status. Serological screening with hepatitis B surface antigen (HBsAg), and antibodies to hepatitis B surface (anti-HBs) and core (anti-HBc) proteins is a key element in the management of IBD patients and, ideally, should be performed at IBD diagnosis. Stratification of individual cases should be done according to the serologic profile and the IBD-specific treatment, with particular emphasis in patients receiving immunosuppressive regimens. In patients who have not contracted HBV, vaccination is indicated to accomplish protective immunity. Vaccination in immunosuppressed patients, however, is a challenging issue and several strategies for primary and revaccination have been proposed. The risk of HBV reactivation in patients with IBD should be considered in both HBsAg-positive and HBsAg-negative/anti-HBc-positive patients, when immunosuppressive therapies are administered. HBV reactivation is preventable via the administration of prophylactic nucleot(s)ide analogues and should be the standard approach in HBsAg-positive patients. HBsAg-negative/anti-HBc-positive patients represent a non-homogeneous group and bear a significantly lower risk of HBV reactivation. Biochemical, serological and molecular monitoring is currently the recommended approach for anti-HBc patients. Acute HBV infection is rarely reported in IBD patients. In the present review, we outline the problems associated with HBV infection in patients with IBD and present updated evidence for their management.

show abstract

“…In fact, while genetics may contribute to early-onset IBD, environmental factors are likely to be critical in late-onset IBD. Prior studies have identified a history of enteric infection, gut dysbiosis, medication use and changes in the innate immune system as risk factors for late-onset IBD, although these studies are largely retrospective 4 7. Obesity is another important environmental factor that is possibly linked to development of IBD.…”

Section: Introductionmentioning

confidence: 99%

Obesity among those newly diagnosed with Crohn’s disease and ulcerative colitis compared with the general population

Sehgal

Shen

et al. 2022

Frontline Gastroenterol

View full text Add to dashboard Cite

ObjectiveObesity is a potentially modifiable risk factor for inflammatory bowel disease (IBD). We aimed to evaluate the body mass index (BMI) of those diagnosed with IBD early versus late in life in the context of age-adjusted background population.Design/methodPatients with a new diagnosis of IBD from 2000 to 2021 were included. Early-onset IBD was classified as age <18 and late-onset IBD classified as age ≥65. Obesity was classified as BMI ≥30 kg/m2. Population data were obtained from community surveys.ResultsIncluded were 1573 patients (56.0%) with Crohn’s disease (CD) and 1234 (44.0%) with ulcerative colitis (UC). Overall, the median BMI at IBD diagnosis was 20 kg/m2(IQR 18–24) among those diagnosed at age <18 vs 26.9 kg/m2(IQR 23.1–30.0) among those diagnosed at age ≥65 (rank-sum p<0.01). In all age groups, BMI was stable during the 1-year preceding IBD diagnosis. At age <18, 11.5% of the background population was obese compared with 3.8% of those with newly diagnosed CD (p<0.01) and 4.8% of those with newly diagnosed UC (p=0.05). At age ≥65, 23.6% of the population was obese compared with 24.3% of those with newly diagnosed CD (p=0.78) and 29.5% of those with newly diagnosed UC (p=0.01).ConclusionPatients with IBD diagnosed at age <18 were less likely to be obese compared with the age-adjusted background population whereas those diagnosed at age ≥65 were more likely to be obese. Future prospective studies should investigate obesity as a modifiable risk factor for late-life IBD.

show abstract

Lower response to the hepatitis B vaccine in future inflammatory bowel disease patients

Cited by 3 publications

References 5 publications

Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy

Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy

Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment

Obesity among those newly diagnosed with Crohn’s disease and ulcerative colitis compared with the general population

Contact Info

Product

Resources

About